TIL Instil Bio, Inc.
USHealthcareAs of 2026-08-24
Why TIL matters now
Instil Bio, Inc. (TIL) is a US stock in Healthcare. The latest InvestLog snapshot shows $7.72 with +1.85% on the session and $52.4M in market capitalization; recent performance reads 1-month -6.48% and YTD -31.82%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-4.2M, and EPS of $-0.62. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -66.4%.
The latest indexable market news headline is "Instil Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update" from GlobeNewsWire.
Additional event context on this page matters because analyst consensus is Hold with a median target of $7.00; recent insider activity includes Binder Gwendolyn filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
0.46
P/S
0.00
EV/EBITDA
-3.15
DCF Value
$-11.77
FCF Yield
-66.4%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-39.8%
ROA
-23.6%
ROIC
-27.6%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-4.2M | $-0.62 |
| Q4 2025 | $0.00 | $-8.2M | $-1.21 |
| FY 2025 | $0.00 | $-71.4M | $-10.70 |
| Q3 2025 | $0.00 | $-13.6M | $-2.01 |
Analyst Ratings
Consensus
Hold
Target (Consensus)
$7.00
Target (Median)
$7.00
Target Range
$7.00 - $7.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
1.91
Instil Bio, Inc. operates as a clinical-stage biopharmaceutical firm, concentrating its efforts on devising novel therapeutic options for individuals battling cancer. A cornerstone of their research involves the advancement of autologous tumor-infiltrating lymphocyte (TIL) cell therapies. Their developmental portfolio features ITIL-168, currently under investigation for a range of malignancies including melanoma, cutaneous squamous cell carcinoma, non-small cell lung cancer, head and neck squamous cell carcinoma, and cervical cancer. Another promising candidate, ITIL-306, is engineered to identify folate receptor alpha (FOLR1) and is being explored for gynecological cancers, non-small cell lung cancer, renal cancer, and other conditions. This company was founded in 2018 and has its principal office situated in Dallas, Texas.